277 related articles for article (PubMed ID: 35033458)
1. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Malik AH; Gupta R; Chakraborty S; Mahajan P; Bandyopadhyay D; Yandrapalli S; Zaid S; Sreenivasan J; Chaturvedi A; Mehta SS; Vyas AV; Patel NC; Combs WG; Ahmad H
Cardiovasc Revasc Med; 2022 Aug; 41():115-121. PubMed ID: 35033458
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ
Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066
[TBL] [Abstract][Full Text] [Related]
3. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Jiang M; You JH
Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
[TBL] [Abstract][Full Text] [Related]
4. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
[TBL] [Abstract][Full Text] [Related]
5. Risk of major adverse cardiovascular events of
Biswas M; Kali MSK; Biswas TK; Ibrahim B
Platelets; 2021 Jul; 32(5):591-600. PubMed ID: 32664772
[TBL] [Abstract][Full Text] [Related]
6. De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis.
De Filippo O; Piroli F; Bruno F; Bocchino PP; Saglietto A; Franchin L; Angelini F; Gallone G; Rizzello G; Ahmad M; Gasparini M; Chatterjee S; De Ferrari GM; D'Ascenzo F
BMJ Evid Based Med; 2024 May; 29(3):171-186. PubMed ID: 38242567
[TBL] [Abstract][Full Text] [Related]
7. Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
Hou M; Hyun K; Chew DP; Kritharides L; Amos D; Brieger D
Heart Lung Circ; 2022 Aug; 31(8):1085-1092. PubMed ID: 35589483
[TBL] [Abstract][Full Text] [Related]
8. Meta-Analysis Comparing P2Y
Baldetti L; Melillo F; Moroni F; Gallone G; Pagnesi M; Venuti A; Beneduce A; Calvo F; Gramegna M; Godino C; D'Ascenzo F; De Ferrari GM; Capodanno D; Cappelletti AM
Am J Cardiol; 2020 Jun; 125(12):1815-1822. PubMed ID: 32305225
[TBL] [Abstract][Full Text] [Related]
9. A Genotype-Guided Strategy for Oral P2Y
Claassens DMF; Vos GJA; Bergmeijer TO; Hermanides RS; van 't Hof AWJ; van der Harst P; Barbato E; Morisco C; Tjon Joe Gin RM; Asselbergs FW; Mosterd A; Herrman JR; Dewilde WJM; Janssen PWA; Kelder JC; Postma MJ; de Boer A; Boersma C; Deneer VHM; Ten Berg JM
N Engl J Med; 2019 Oct; 381(17):1621-1631. PubMed ID: 31479209
[TBL] [Abstract][Full Text] [Related]
10. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
Wang Z; Zhou DY; Su Y; Si LY; Xu Q
BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560
[TBL] [Abstract][Full Text] [Related]
11. P2Y12 Inhibitors for Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis.
Fujisaki T; Kuno T; Briasoulis A; Misumida N; Takagi H; Latib A
Tex Heart Inst J; 2023 May; 50(3):. PubMed ID: 37302149
[TBL] [Abstract][Full Text] [Related]
12. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y
O'Donoghue ML; Murphy SA; Sabatine MS
Circulation; 2020 Aug; 142(6):538-545. PubMed ID: 32551860
[TBL] [Abstract][Full Text] [Related]
13. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
[TBL] [Abstract][Full Text] [Related]
14. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
Westman PC; Lipinski MJ; Torguson R; Waksman R
Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
[TBL] [Abstract][Full Text] [Related]
15. Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis.
Komosa A; Lesiak M; Krasiński Z; Grygier M; Siniawski A; Skorupski W; Olasińska-Wiśniewska A; Pyda M; Araszkiewicz A; Mitkowski P; Grajek S; Mularek-Kubzdela T; Hengstenberg C; Siller-Matula JM
Thromb Haemost; 2019 Jun; 119(6):1000-1020. PubMed ID: 30919382
[TBL] [Abstract][Full Text] [Related]
16. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
Gan XD; Wei BZ; Fang D; Fang Q; Li KY; Ding SL; Peng S; Wan J
Curr Med Res Opin; 2015 Dec; 31(12):2313-23. PubMed ID: 26402735
[TBL] [Abstract][Full Text] [Related]
18. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
AlMukdad S; Elewa H; Al-Badriyeh D
J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes.
Dong OM; Friede KA; Chanfreau-Coffinier C; Voora D
Eur Heart J Qual Care Clin Outcomes; 2023 Apr; 9(3):249-257. PubMed ID: 35652783
[TBL] [Abstract][Full Text] [Related]
20. Prasugrel in the treatment of acute coronary syndrome.
Spartalis M; Tzatzaki E; Spartalis E; Paschou SA; Athanasiou A; Iliopoulos DC; Siasos G; Voudris V
Future Cardiol; 2020 Nov; 16(6):559-568. PubMed ID: 32390477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
